Keyphrases
Hypertension Management
100%
Asymmetric Dimethylarginine
100%
Nebivolol
100%
Metoprolol
64%
Growth Factors
23%
Insulin-like
23%
Augmentation Index
23%
Endothelial Progenitor Cells
23%
β-adrenergic Receptor
23%
Cell number
17%
Nitric Oxide
17%
Endothelial Nitric Oxide Synthase (eNOS)
17%
Metoprolol Succinate
17%
Hypertensive Patients
11%
Adrenergic Receptors Subtypes
11%
Agonism
11%
β-Adrenergic Receptor Antagonists
11%
Washout Period
5%
Blood Pressure
5%
Systolic Blood Pressure
5%
Arginine
5%
Statistical Analysis
5%
Randomized Controlled Trial
5%
Placebo
5%
Metabolic Parameters
5%
Beta-blockers
5%
Cell Culture
5%
Diabetic Subjects
5%
Diabetic
5%
Heart Rate
5%
Single Center
5%
Cardiology
5%
Cyclic GMP
5%
Plasma Concentration
5%
Extended Release
5%
Endothelial Dysfunction
5%
Stiffness
5%
Peripheral Blood
5%
Hemodynamic Parameters
5%
Preclinical Data
5%
Daily Dose
5%
Nitric Oxide Production
5%
Large Arteries
5%
Vascular Endothelium
5%
Applanation Tonometry
5%
Baseline Blood Pressure
5%
Nitric Oxide Level
5%
Vascular Tone
5%
Blood Pressure Target
5%
Type 2 Diabetic
5%
Blood Pressure Indices
5%
Hypertensive Subjects
5%
Antagonist Activity
5%
Optimal Benefits
5%
ELISA Method
5%
Cardiovascular Control
5%
Beta-adrenergic Receptor Blocker
5%
Dimethylarginine Dimethylaminohydrolase
5%
Pressure Augmentation
5%
Neuroscience
6 N,n' Dimethylarginine
100%
Blood Plasma
100%
Nebivolol
100%
Metoprolol
82%
Nitric Oxide
29%
Insulin-Like Growth Factor 1
23%
Progenitor Cell
23%
Beta Adrenergic Receptor
17%
Succinate
17%
Receptor Antagonist
11%
Nitric Oxide Synthase
11%
Receptor Subtype
11%
Beta-3 Adrenergic Receptor
11%
Arginine
5%
Randomized Controlled Trial
5%
Agonist
5%
Placebo
5%
Cell Culture
5%
Cyclic Guanosine Monophosphate
5%
Diabetes Mellitus
5%
Adrenergic Receptor
5%
ELISA
5%
Vasoactive
5%
Beta Blocker
5%
Endothelial Nitric Oxide Synthase
5%
Adrenergic
5%
Dimethylargininase
5%
Beta-1 Adrenergic Receptor
5%
Pharmacology, Toxicology and Pharmaceutical Science
6 N,n' Dimethylarginine
100%
N(g),n(g) Dimethylarginine
100%
Nebivolol
100%
Metoprolol
64%
Nitric Oxide
29%
Somatomedin C
23%
Metoprolol Succinate
17%
Beta Adrenergic Receptor Blocking Agent
11%
Nitric Oxide Synthase
11%
Receptor Subtype
11%
Beta 3 Adrenergic Receptor
11%
Beta 1 Adrenergic Receptor Blocking Agent
11%
Randomized Controlled Trial
5%
Placebo
5%
Diabetes Mellitus
5%
Enzyme-Linked Immunosorbent Assay
5%
Endothelial Dysfunction
5%
Cell Culture
5%
Arginine
5%
Vasoactive Agent
5%
Adrenergic Receptor
5%
Cyclic GMP
5%
Endothelial Nitric Oxide Synthase
5%
Dimethylargininase
5%
Beta 1 Adrenergic Receptor
5%